2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Meghan Thompson, MD, third-year fellow, Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, discusses future research directions in chronic lymphocytic leukemia (CLL).
Although several therapies are available to treat patients with CLL, many patients experience disease progression, Thompson says. As such, developing a greater understanding of how to best tailor available therapies to patients is of paramount importance, Thompson explains.
Additionally, the development of improved treatment sequencing of monotherapies or combinations could further improve outcomes for patients with CLL, Thompson concludes.
Related Content: